Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

INTRODUCTION: The aim of the analysis was to characterize the population pharmacokinetics (PKs) and exposure–response (E–R) for efficacy (fasting plasma glucose, glycated hemoglobin) and safety/tolerability [hypoglycemia, genital infections, urinary tract infection (UTI), and volume depletion] of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Baron, Kyle T., Macha, Sreeraj, Broedl, Uli C., Nock, Valerie, Retlich, Silke, Riggs, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014782/
https://www.ncbi.nlm.nih.gov/pubmed/27312794
http://dx.doi.org/10.1007/s13300-016-0174-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014782/
https://www.ncbi.nlm.nih.gov/pubmed/27312794
http://dx.doi.org/10.1007/s13300-016-0174-y

Ejemplares similares